Calyxt files complaint in Delaware Chancery Court against Bayer CropScience
Mar. 13, 2018
In December 2013, Calyxt entered into a Research and Commercial License Agreement with Bayer pursuant to which it granted Bayer a license to certain patents for the research and commercialization of products developed with TALEN® technology. Calyxt believes that Bayer has breached the License Agreement by filing patent applications in violation of the License Agreement's provisions and by failing to make a payment due under the License Agreement. Calyxt previously gave notice to Bayer of termination of the License Agreement, and today filed a complaint in Delaware Chancery Court requesting a declaration that the License Agreement has terminated for material breach and an order of specific performance requiring Bayer to comply with its post-termination obligations.
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).